E8. Prevention of breast and gynaecological tumours when there is a proven genetic risk: a review  by unknown
E8. Prevention of breast and gynaecological tumours when
there is a proven genetic risk: a review
Eric de Jonge
Ziekenhuis Oost-Limburg Campus St Jan, Genk, Belgium
As genetic testing for cancer risk assessment enters
the clinical mainstream, gynaecologists are increasingly
required to provide guidance to women with a proven
genetic risk, speciﬁcally regarding risk-reduction man-
agement. We reviewed the current status of knowledge
on this topic for women diagnosed with pathogenic
germline mutations, BRCA1/BRCA2 mutation carriers
being at risk for breast and ovarian cancer, and MLH1/
MSH6 mutation carriers (hereditary non-polyposis col-
orectal cancer syndrome or HNPCC) at risk for en-
dometrial and ovarian cancers.
Risk-reduction options include increased surveil-
lance, chemoprevention, and prophylactic surgery. In
HNPCC, the beneﬁt of screening for endometrial and
ovarian cancer is uncertain and of secondary importance
to regular colonoscopy [1]. Expert opinion recommends
to discuss the option of a prophylactic hysterectomy and
bilateral salpingo-oophorectomy at the time of colonic
resection for women with HNPCC-associated colorectal
cancer [2].
Breast cancers in BRCA1/BRCA2 mutation carriers
are characterised by early onset [3,4] and risk of sec-
ond primary breast cancer [5]. Screening re-
commendations for ovarian cancer using an algorithm
of CA125 and transvaginal ultrasound are based on
expert opinion only, without evidence of an improved
early detection rate or eﬀect on mortality. The same
goes for breast cancer screening where it is recommend
that yearly mammo-echography should start not later
than age 30 years [6]. However, mammography in this
setting has a low sensitivity and poor compliance, but
the promising results with magnetic resonance imaging
(MRI) should be explored further [7]. As a strategy,
surveillance remains inferior to other risk-reduction
measures in BRCA1/BRCA2 mutation carriers [8,9].
Arguments to promote chemoprevention with ta-
moxifen in BRCA1/BRCA2 mutation carriers are hard
to ﬁnd: the results of a sub-analysis of BRCA1/
BRCA2 mutation carriers in the National Surgical
Adjuvant Breast and Bowel Project (NSABP)-P1 trial
were inconclusive [10]. One case-controlled study
showed a 50% reduction of contralateral breast cancer
[11]. Moreover 70–80% of breast cancers in BRCA1/
BRCA2 mutation carriers are oestrogen-receptor-ne-
gative. The results of the chemoprevention study with
raloxifene are awaited.
The risk-beneﬁt eﬀect of oral contraceptives in
BRCA1/BRCA2 mutation carriers is controversial and
has remained unexplored so far in HNPCC women with
regard to the ovarian cancer risk [12,13].
Clinical data on prophylactic surgery in asympto-
matic BRCA1/BRCA2 mutation carriers are more reli-
able, though the level of evidence is largely limited to
results from retrospective and case-control studies.
Prophylactic bilateral mastectomy (PBM) is most eﬀec-
tive (>90% risk-reduction), but remains controversial
not least because the prevention strategy is more radical
than the cure [3,4]. However, prophylactic salpingo-
oophorectomy (PSO) is more acceptable and able to
reduce the risk of both breast and ovarian cancer (53–
75% and 85–96%. respectively) [14,15].
Survival estimates, expressed as years in life ex-
pectancy gained, obtained from decision analysis
models, help physicians to communicate the antici-
pated eﬀects of various cancer prevention strategies on
health outcomes for BRCA1/BRCA2 mutation carriers.
They learn that prophylactic surgery for breast cancer
has a signiﬁcant eﬀect on survival that is inﬂuenced by
procedure (PBM plus PSO > PBM > PSO), by age at
intervention, the level of mutation penetrance, and
prior PSO. The absolute gain in life expectancy by
PBM was more pronounced if performed at an earlyE-mail address: dr.e.de.jonge@pandora.be.
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age and in women with a high phenotypic mutation
penetrance, tailed oﬀ after prior PSO and disappeared
when performed after the age of 50 years [8,9]. How-
ever, PSO may be delayed until age 40 years or com-
pletion of childbearing without loss of life-expectancy
[9]. The acceptance of prophylactic surgery is study-
dependent, but generally low, with PSO being more
acceptable than PBM [3]. A speciﬁc group of young
women with a high personal cancer risk estimate and
who reported high levels of cancer worry were more
likely to consider PBM. Quality of life-adjusted survi-
val estimates taking into consideration the disﬁguring
eﬀects of prophylactic surgery, promote PSO followed
by hormonal replacement therapy until the age of 50
years rather than PBM [8,9]. Women with a BRCA1/
BRCA2 gene mutation who have developed breast
cancer have a 12–20% risk of subsequent contralateral
breast cancer [5]. Few data are available on the eﬃcacy
of interventions to reduce the risk of contralateral
breast cancer in BRCA1/BRCA2 mutation carriers.
However, their impact on gain in life expectancy was
less than in asymptomatic BRCA1/BRCA2 mutation
carriers and depended on the prognosis of the primary
breast cancer they were treated for [16].
It has been pointed out that speciﬁc methodolo-
gical problems associated with research evaluating the
eﬃcacy of prophylactic surgery results in an over-
estimation of its beneﬁt [17]. A similar overestimation
is noted in decision analysis models as the gains in
life expectancy projected only apply to women des-
tined to die from their cancer, while the more fa-
vourable outcomes (asymptomatic or recurrence-free
life) are not taken into account [18]. Further research
therefore does not only require prospective cohort
studies to eliminate various selection biases, but also
a reﬁning and validation of the risk estimates which
we develop in decision analysis models is needed.
This will ultimately enable the clinician to counsel his
patients more accurately.
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